Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.
Identifieur interne : 001866 ( Ncbi/Curation ); précédent : 001865; suivant : 001867Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.
Auteurs : Joong-Seok Kim [Corée du Sud] ; Phil-Hyu Lee ; Kwang-Soo Lee ; Jeong-Wook Park ; Yeong-In Kim ; Yong-An Chung ; Sung-Hoon Kim ; Seung-Hyun Kim ; Juhan Kim ; Yun-Young Choi ; Hee-Tae KimSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- 3-Iodobenzylguanidine (diagnostic use), 3-Iodobenzylguanidine (pharmacokinetics), Aged, Aged, 80 and over, Case-Control Studies, Cerebrovascular Disorders (drug therapy), Cerebrovascular Disorders (metabolism), Cerebrovascular Disorders (radionuclide imaging), Female, Heart (physiopathology), Heart (radionuclide imaging), Humans, Male, Middle Aged, Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (metabolism), Parkinsonian Disorders (radionuclide imaging), Radionuclide Imaging (methods), Radiopharmaceuticals (diagnostic use), Radiopharmaceuticals (pharmacokinetics).
- MESH :
- chemical , diagnostic use : 3-Iodobenzylguanidine, Radiopharmaceuticals.
- chemical , pharmacokinetics : 3-Iodobenzylguanidine, Radiopharmaceuticals.
- drug therapy : Cerebrovascular Disorders, Parkinsonian Disorders.
- metabolism : Cerebrovascular Disorders, Parkinsonian Disorders.
- methods : Radionuclide Imaging.
- physiopathology : Heart.
- radionuclide imaging : Cerebrovascular Disorders, Heart, Parkinsonian Disorders.
- Aged, Aged, 80 and over, Case-Control Studies, Female, Humans, Male, Middle Aged.
Abstract
The purpose of our study was to prospectively evaluate cardiac [(123)I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during the course of their CVD were enrolled in the study; 16 age-matched subjects, and 30 patients with Parkinson's disease (PD) were also evaluated with cardiac MIBG uptake. MIBG uptake was assessed using the ratio of the heart to the upper mediastinum (H/M) according to planar scintigraphic data. The mean H/M ratio was significantly higher in patients with VP than in those with PD (2.28 +/- 0.41 vs. 1.27 +/- 0.13; P < 0.001). MIBG uptake did not differ between VP and controls (2.46 +/- 0.33; P > 0.05). Our findings suggest that myocardial postganglionic sympathetic dysfunction found in PD is absent in most patients with VP. MIBG single photon emission computed tomography imaging may be useful to help distinguish between PD and VP patients in clinical practice.
DOI: 10.1002/mds.21112
PubMed: 16991157
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002A73
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002A73
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002E35
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001866
Links to Exploration step
pubmed:16991157Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.</title>
<author><name sortKey="Kim, Joong Seok" sort="Kim, Joong Seok" uniqKey="Kim J" first="Joong-Seok" last="Kim">Joong-Seok Kim</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Neurology, The Catholic University of Korea, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lee, Phil Hyu" sort="Lee, Phil Hyu" uniqKey="Lee P" first="Phil-Hyu" last="Lee">Phil-Hyu Lee</name>
</author>
<author><name sortKey="Lee, Kwang Soo" sort="Lee, Kwang Soo" uniqKey="Lee K" first="Kwang-Soo" last="Lee">Kwang-Soo Lee</name>
</author>
<author><name sortKey="Park, Jeong Wook" sort="Park, Jeong Wook" uniqKey="Park J" first="Jeong-Wook" last="Park">Jeong-Wook Park</name>
</author>
<author><name sortKey="Kim, Yeong In" sort="Kim, Yeong In" uniqKey="Kim Y" first="Yeong-In" last="Kim">Yeong-In Kim</name>
</author>
<author><name sortKey="Chung, Yong An" sort="Chung, Yong An" uniqKey="Chung Y" first="Yong-An" last="Chung">Yong-An Chung</name>
</author>
<author><name sortKey="Kim, Sung Hoon" sort="Kim, Sung Hoon" uniqKey="Kim S" first="Sung-Hoon" last="Kim">Sung-Hoon Kim</name>
</author>
<author><name sortKey="Kim, Seung Hyun" sort="Kim, Seung Hyun" uniqKey="Kim S" first="Seung-Hyun" last="Kim">Seung-Hyun Kim</name>
</author>
<author><name sortKey="Kim, Juhan" sort="Kim, Juhan" uniqKey="Kim J" first="Juhan" last="Kim">Juhan Kim</name>
</author>
<author><name sortKey="Choi, Yun Young" sort="Choi, Yun Young" uniqKey="Choi Y" first="Yun-Young" last="Choi">Yun-Young Choi</name>
</author>
<author><name sortKey="Kim, Hee Tae" sort="Kim, Hee Tae" uniqKey="Kim H" first="Hee-Tae" last="Kim">Hee-Tae Kim</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="doi">10.1002/mds.21112</idno>
<idno type="RBID">pubmed:16991157</idno>
<idno type="pmid">16991157</idno>
<idno type="wicri:Area/PubMed/Corpus">002A73</idno>
<idno type="wicri:Area/PubMed/Curation">002A73</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002E35</idno>
<idno type="wicri:Area/Ncbi/Merge">001866</idno>
<idno type="wicri:Area/Ncbi/Curation">001866</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.</title>
<author><name sortKey="Kim, Joong Seok" sort="Kim, Joong Seok" uniqKey="Kim J" first="Joong-Seok" last="Kim">Joong-Seok Kim</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Neurology, The Catholic University of Korea, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lee, Phil Hyu" sort="Lee, Phil Hyu" uniqKey="Lee P" first="Phil-Hyu" last="Lee">Phil-Hyu Lee</name>
</author>
<author><name sortKey="Lee, Kwang Soo" sort="Lee, Kwang Soo" uniqKey="Lee K" first="Kwang-Soo" last="Lee">Kwang-Soo Lee</name>
</author>
<author><name sortKey="Park, Jeong Wook" sort="Park, Jeong Wook" uniqKey="Park J" first="Jeong-Wook" last="Park">Jeong-Wook Park</name>
</author>
<author><name sortKey="Kim, Yeong In" sort="Kim, Yeong In" uniqKey="Kim Y" first="Yeong-In" last="Kim">Yeong-In Kim</name>
</author>
<author><name sortKey="Chung, Yong An" sort="Chung, Yong An" uniqKey="Chung Y" first="Yong-An" last="Chung">Yong-An Chung</name>
</author>
<author><name sortKey="Kim, Sung Hoon" sort="Kim, Sung Hoon" uniqKey="Kim S" first="Sung-Hoon" last="Kim">Sung-Hoon Kim</name>
</author>
<author><name sortKey="Kim, Seung Hyun" sort="Kim, Seung Hyun" uniqKey="Kim S" first="Seung-Hyun" last="Kim">Seung-Hyun Kim</name>
</author>
<author><name sortKey="Kim, Juhan" sort="Kim, Juhan" uniqKey="Kim J" first="Juhan" last="Kim">Juhan Kim</name>
</author>
<author><name sortKey="Choi, Yun Young" sort="Choi, Yun Young" uniqKey="Choi Y" first="Yun-Young" last="Choi">Yun-Young Choi</name>
</author>
<author><name sortKey="Kim, Hee Tae" sort="Kim, Hee Tae" uniqKey="Kim H" first="Hee-Tae" last="Kim">Hee-Tae Kim</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3-Iodobenzylguanidine (diagnostic use)</term>
<term>3-Iodobenzylguanidine (pharmacokinetics)</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Case-Control Studies</term>
<term>Cerebrovascular Disorders (drug therapy)</term>
<term>Cerebrovascular Disorders (metabolism)</term>
<term>Cerebrovascular Disorders (radionuclide imaging)</term>
<term>Female</term>
<term>Heart (physiopathology)</term>
<term>Heart (radionuclide imaging)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Parkinsonian Disorders (metabolism)</term>
<term>Parkinsonian Disorders (radionuclide imaging)</term>
<term>Radionuclide Imaging (methods)</term>
<term>Radiopharmaceuticals (diagnostic use)</term>
<term>Radiopharmaceuticals (pharmacokinetics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>3-Iodobenzylguanidine</term>
<term>Radiopharmaceuticals</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>3-Iodobenzylguanidine</term>
<term>Radiopharmaceuticals</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cerebrovascular Disorders</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Cerebrovascular Disorders</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radionuclide Imaging</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Heart</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Cerebrovascular Disorders</term>
<term>Heart</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Case-Control Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose of our study was to prospectively evaluate cardiac [(123)I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during the course of their CVD were enrolled in the study; 16 age-matched subjects, and 30 patients with Parkinson's disease (PD) were also evaluated with cardiac MIBG uptake. MIBG uptake was assessed using the ratio of the heart to the upper mediastinum (H/M) according to planar scintigraphic data. The mean H/M ratio was significantly higher in patients with VP than in those with PD (2.28 +/- 0.41 vs. 1.27 +/- 0.13; P < 0.001). MIBG uptake did not differ between VP and controls (2.46 +/- 0.33; P > 0.05). Our findings suggest that myocardial postganglionic sympathetic dysfunction found in PD is absent in most patients with VP. MIBG single photon emission computed tomography imaging may be useful to help distinguish between PD and VP patients in clinical practice.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001866 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001866 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:16991157 |texte= Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:16991157" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |